US · Healthcare · Biotechnology
EPS came in at -0.35 against a street estimate of -0.46 — a beat of 23.9%.
Analysts rate Verastem Inc a strong buy (10 buy, 0 hold, 0 sell out of 10) with an average price target of $17.11.
| Fund | Stake |
|---|---|
| BlackRock Inc | 7.57% |
| Nantahala Capital Management, LLC | 5.90% |
| Armistice Capital, LLC | 5.78% |
| RTW INVESTMENTS, LLC | 5.46% |
| Deep Track Capital, LP | 4.72% |
| State Street Corp | 4.23% |
| Rosalind Advisors, Inc. | 3.28% |
| Vanguard Capital Management, LLC | 3.17% |
| Document | Date |
|---|---|
| Company announcement · Q4 2026 HEADLINE NUMBERS • Verastem entered an underwriting agreement on October 14, 2026, to sell 30,937,500 shares of common stock and pre-funded warrants | 2026-10-14 |
| Results announced · Q4 2026 HEADLINE NUMBERS • Verastem presented preliminary clinical data for VS-7375, an investigational selective KRAS G12D inhibitor; it is not approved by | 2026-10-14 |
| Material agreement · Q3 2026 VERASTEM, INC. (VSTM) - FORM 8-K SUMMARY HEADLINE NUMBERS • Total financing available: Up to $150 million in senior secured notes ($75 million Initi | 2026-08-07 |
| Quarterly report · Q2 2026 VERASTEM, INC. - SUMMARY FOR RETAIL INVESTORS HEADLINE NUMBERS • Cash Position: $136.4 million as of June 30, 2026, down from $205.0 million at Dece | 2026-08-06 |
| Results announced · Q3 2026 VERASTEM ONCOLOGY Q2 2026 FINANCIAL RESULTS SUMMARY HEADLINE NUMBERS • Q2 2026 net product revenue: $25.1 million (AVMAPKI FAKZYNJA CO-PACK combinat | 2026-08-06 |
| Reg FD disclosure · Q2 2026 VERASTEM, INC. – FORM 8-K SUMMARY HEADLINE NUMBERS • Company announced preliminary efficacy data from TARGET-D 101 Phase 1/2 clinical trial as of Ju | 2026-06-23 |
| Reg FD disclosure · Q2 2026 VERASTEM, INC. - FORM 8-K SUMMARY HEADLINE NUMBERS • Company: Verastem, Inc. (ticker: VSTM, Nasdaq Capital Market) • Headquarters: 117 Kendrick Stre | 2026-06-17 |
| Quarterly report · Q1 2026 VERASTEM, INC. – Q1 2026 SUMMARY FOR RETAIL INVESTORS --- HEADLINE NUMBERS • Cash and equivalents: $165.6 million (March 31, 2026) vs. $205.0 milli | 2026-05-07 |
Readable in the app.
| Announcement | Date |
|---|---|
| Intent to form strategic collaboration with Erasca to evaluate combination cancer treatment Verastem reported encouraging preliminary clinical data for VS-7375, its investigational oral KRAS G12D inhibitor, in the ongoing TARGET-D 101 Phase 1/2 trial. Activity was seen in pancreati | 2026-06-23 |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Verastem Inc — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-11-07.